Emma Ingleson

404 total citations
14 papers, 255 citations indexed

About

Emma Ingleson is a scholar working on Hematology, General Health Professions and Molecular Biology. According to data from OpenAlex, Emma Ingleson has authored 14 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in General Health Professions and 5 papers in Molecular Biology. Recurrent topics in Emma Ingleson's work include Multiple Myeloma Research and Treatments (7 papers), Health Policy Implementation Science (4 papers) and Protein Degradation and Inhibitors (4 papers). Emma Ingleson is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Health Policy Implementation Science (4 papers) and Protein Degradation and Inhibitors (4 papers). Emma Ingleson collaborates with scholars based in United Kingdom. Emma Ingleson's co-authors include Thomas A. Willis, Liz Glidewell, Robbie Foy, Rosemary McEachan, Rebecca Lawton, Gemma Louch, Jane Heyhoe, Linda Clare, Penny Wright and Simon Pini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Emma Ingleson

14 papers receiving 248 citations

Peers

Emma Ingleson
Comparison fields: 5 of 64
  • General Health Professions 93
  • Hematology 82
  • Molecular Biology 72
  • Oncology 62
  • Public Health, Environmental and Occupational Health 35
Replace Thomas V. Joshua with:
Thomas V. Joshua United States
Karl Fernstrom United States
Uzor C. Ogbu United States
Caroline McKay United States
Joanne Bayly United Kingdom
P J Carey United Kingdom
Suman Pramanik India
Lauren Nisotel United States
Sheela Upadhyaya United Kingdom
Linda Garrett United States
Thomas V. Joshua United States View profile →
Citations per field, relative to Emma Ingleson
Emma Ingleson · 1×
Citations per year, relative to Emma Ingleson
Emma Ingleson · 1×

Countries citing papers authored by Emma Ingleson

Since Specialization
Citations

This map shows the geographic impact of Emma Ingleson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Ingleson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Ingleson more than expected).

Fields of papers citing papers by Emma Ingleson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Ingleson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Ingleson. The network helps show where Emma Ingleson may publish in the future.

Co-authorship network of co-authors of Emma Ingleson

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Ingleson. A scholar is included among the top collaborators of Emma Ingleson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Ingleson. Emma Ingleson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
# Work Indexed citations
1
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
2023 ·Journal of Clinical Oncology ·Martin Kaiser, Andrew Hall, Katrina Walker, Amy L. Sherborne, Ruth M. de Tute, (unknown), (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah Brown, Matthew Jenner
54
2
Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial
2022 ·Blood ·Martin Kaiser, Andrew Hall, Isabelle L Smith, Ruth M. de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner
9
3
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.
2021 ·Journal of Clinical Oncology ·Martin Kaiser, Andrew Hall, Katrina Walker, Ruth de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner
11
4
Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
2021 ·Blood ·Matthew Jenner, Andrew Hall, Sian Faustini, (unknown), Ruth M. de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Roger G. Owen, Sarah Brown, Mark T. Drayson, Martin Kaiser
2
5
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial
2021 ·Blood ·Martin Kaiser, Andrew Hall, Katrina Walker, (unknown), Ruth M. de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah Brown, Matthew Jenner
8
6
OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial
2021 ·Clinical Lymphoma Myeloma & Leukemia ·Martin Kaiser, Andrew Hall, Katrina Walker, Ruth de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner
1
7
Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients
2019 ·Blood ·Sarah Brown, Andrew Hall, (unknown), Emma Ingleson, Louise Flanagan, Holger W. Auner, Kevin Boyd, Mamta Garg, Martin Kaiser
1
8
Development of an Item Pool for a Needs-Based Measure of Quality of Life of Carers of a Family Member with Dementia
2018 ·Patient ·Jan R. Oyebode, Simon Pini, Emma Ingleson, (unknown), Mike Horton, Linda Clare, Hareth Al‐Janabi, Carol Brayne, Penny Wright
12
9
To what extent can behaviour change techniques be identified within an adaptable implementation package for primary care? A prospective directed content analysis
2018 ·Implementation Science ·(unknown), Liz Glidewell, Thomas A. Willis, Duncan Petty, Rebecca Lawton, Rosemary McEachan, Emma Ingleson, (unknown), (unknown), (unknown), Cheryl Hunter, Suzanne Hartley, Kara Gray‐Burrows, Susan Clamp, Paul Carder, Sarah Alderson, Amanda Farrin, Robbie Foy
23
10
A Needs-led Framework for Understanding the Impact of Caring for a Family Member With Dementia
2017 ·The Gerontologist ·Simon Pini, Emma Ingleson, (unknown), Linda Clare, Penny Wright, Jan R. Oyebode
26
11
Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials
2016 ·International Journal of Radiation Oncology*Biology*Physics ·Patricia Holch, Ann Henry, S.E. Davidson, Alexandra Gilbert, Jacqueline A Routledge, (unknown), K. Franks, Emma Ingleson, (unknown), Galina Velikova
21
12
Using the Theoretical Domains Framework (TDF) to understand adherence to multiple evidence-based indicators in primary care: a qualitative study
2015 ·Implementation Science ·(unknown), Rebecca Lawton, Jane Heyhoe, Gemma Louch, Emma Ingleson, Liz Glidewell, Thomas A. Willis, Rosemary McEachan, Robbie Foy
67
13
Action to Support Practices Implement Research Evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting ‘high impact’ clinical practice recommendations in general practice
2015 ·Implementation Science ·(unknown), Thomas A. Willis, Suzanne Hartley, Liz Glidewell, Amanda Farrin, Rebecca Lawton, Rosemary McEachan, Emma Ingleson, (unknown), Michelle Collinson, Susan Clamp, Cheryl Hunter, Vicky Ward, Claire Hulme, David Meads, (unknown), Paul Carder, Robbie Foy
13
14
Optimising participation and generalisability: the use of opt-out recruitment for an implementation trial in primary care
2015 ·Trials ·Suzanne Hartley, Paul Carder, Robbie Foy, (unknown), Liz Glidewell, Emma Ingleson, (unknown), (unknown), Thomas A. Willis, Amanda Farrin
7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas V. Joshua Breakdown of academic impact, for papers by Karl Fernstrom Breakdown of academic impact, for papers by Uzor C. Ogbu Breakdown of academic impact, for papers by Caroline McKay Breakdown of academic impact, for papers by Joanne Bayly Breakdown of academic impact, for papers by P J Carey Breakdown of academic impact, for papers by Suman Pramanik Breakdown of academic impact, for papers by Lauren Nisotel Breakdown of academic impact, for papers by Sheela Upadhyaya Breakdown of academic impact, for papers by Linda Garrett
Rankless by CCL
2026